Neuromodulation therapies and treatment-resistant depression

Alharbi, Khalid Saad; Qureshi, Naseem Akhtar

doi:10.2147/mder.s33198

Cited by 12 publications

(8 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Co-occurring psychiatric and physical conditions further complicate the treatment of mood disorders 8–11. Standard pharmacological and psychotherapies used in patients with depression have resulted in the following outcomes: 30% of patients remit, another 30% show a partial response, and the rest are resistant to treatment 12,13. Overall, 30%–40% of patients with major depression would benefit from CAM 12,13.…”

Section: Discussionmentioning

confidence: 99%

“…Standard pharmacological and psychotherapies used in patients with depression have resulted in the following outcomes: 30% of patients remit, another 30% show a partial response, and the rest are resistant to treatment 12,13. Overall, 30%–40% of patients with major depression would benefit from CAM 12,13. Open-label clinical trials of CAM are more abundant than randomized controlled trials.…”

Section: Discussionmentioning

confidence: 99%

“…However, 30%–40% of patients with major depression become resistant to these treatments as a result of medical comorbidity, unavailability of appropriate services, and poor adherence with available therapies. These difficult-to-treat patients need specialized treatment strategies 12,13. The two major classifications of mental disorders provide a comprehensive view of mood disorders, but these have now been divided into more than 30 diagnostic categories 14,15.…”

Section: Mood Disordersmentioning

confidence: 99%

“…When nonresponders were augmented or switched to another antidepressant, 30% remitted 26. According to Bambauer et al, patients with treatment-resistant depression attributable to nonadherence with medication27 need augmentation strategies 12,13. Patients with treatment-resistant depression are also at higher risk for relapse 28,29…”

Section: Mood Disordersmentioning

confidence: 99%

See 3 more Smart Citations

Mood disorders and complementary and alternative medicine: a literature review

Qureshi¹,

Al-Bedah²

2013

NDT

123

View full text Add to dashboard Cite

Mood disorders are a major public health problem and are associated with considerable burden of disease, suicides, physical comorbidities, high economic costs, and poor quality of life. Approximately 30%–40% of patients with major depression have only a partial response to available pharmacological and psychotherapeutic interventions. Complementary and alternative medicine (CAM) has been used either alone or in combination with conventional therapies in patients with mood disorders. This review of the literature examines evidence-based data on the use of CAM in mood disorders. A search of the PubMed, Medline, Google Scholar, and Quertile databases using keywords was conducted, and relevant articles published in the English language in the peer-reviewed journals over the past two decades were retrieved. Evidence-based data suggest that light therapy, St John’s wort, Rhodiola rosea, omega-3 fatty acids, yoga, acupuncture, mindfulness therapies, exercise, sleep deprivation, and S-adenosylmethionine are effective in the treatment of mood disorders. Clinical trials of vitamin B complex, vitamin D, and methylfolate found that, while these were useful in physical illness, results were equivocal in patients with mood disorders. Studies support the adjunctive role of omega-3 fatty acids, eicosapentaenoic acid, and docosahexaenoic acid in unipolar and bipolar depression, although manic symptoms are not affected and higher doses are required in patients with resistant bipolar depression and rapid cycling. Omega-3 fatty acids are useful in pregnant women with major depression, and have no adverse effects on the fetus. Choline, inositol, 5-hydroxy-L-tryptophan, and N-acetylcysteine are effective adjuncts in bipolar patients. Dehydroepiandrosterone is effective both in bipolar depression and depression in the setting of comorbid physical disease, although doses should be titrated to avoid adverse effects. Ayurvedic and homeopathic therapies have the potential to improve symptoms of depression, although larger controlled trials are needed. Mind-body-spirit and integrative medicine approaches can be used effectively in mild to moderate depression and in treatment-resistant depression. Currently, although CAM therapies are not the primary treatment of mood disorders, level 1 evidence could emerge in the future showing that such treatments are effective.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Mood Disordersmentioning

confidence: 99%

Section: Mood Disordersmentioning

confidence: 99%

See 2 more Smart Citations

Mood disorders and complementary and alternative medicine: a literature review

Qureshi¹,

Al-Bedah²

2013

NDT

123

View full text Add to dashboard Cite

show abstract

“…The penetration of magnetic flux is similar to that of the traditional magnetic stimulation [9], [16], [47]- [48] which operates at lower frequencies. Then, from equation (6 For further verification, the simulated E field distribution of mode 3 with a piece of muscle tissue (σ = 0.8 S/m, ε r = 56.8 [22]) of the size 24 cm × 12 cm × 4 cm is shown in Fig. 5.31.…”

Section: Effect Of the Medium In Between The Coilsmentioning

confidence: 99%

Design and investigation of novel neural stimulation by magnetic resonance coupling

Pradhan¹

View full text Add to dashboard Cite

Stimulation methods for treatment of neural disorders have evolved tremendously over the years ranging from invasive methods i.e. Deep Brain Stimulation (DBS) to non-invasive methods i.e. Transcutaneous Electric Nerve Stimulation (TENS) and Transcranial Magnetic Stimulation (TMS). This study hence first reviews existing literature for pain mechanism and how electrical stimulation is useful for treatment of pain. The existing commercial treatment options are analyzed to determine the technical drawbacks which could be overcome, to develop a more effective system for therapy.

show abstract

Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy

Kleckner

Jusko

Culakova

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose. Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of taxane and platinum chemotherapy for breast cancer. Clinicians cannot accurately predict CIPN severity partly because its pathophysiology is poorly understood. Although inflammation may play a role in CIPN, there are limited human studies. Here, we identified the strongest predictors of CIPN using variables measured before taxane- or platinum-based chemotherapy, including serum inflammatory markers. Methods. 116 sedentary women with breast cancer (mean age 55 years) rated (1) numbness and tingling and (2) hot/coldness in hands/feet on 0–10 scales before and after six weeks of taxane- or platinum-based chemotherapy. A sub-study was added to collect cytokine data in the final 55 patients. We examined all linear models to predict CIPN severity at 6 weeks using pre-chemotherapy assessments of inflammatory, behavioral, clinical, and psychosocial factors. The final model was selected via goodness of fit. Results. The strongest pre-chemotherapy predictors of numbness and tingling were worse fatigue/anxiety/depression (explaining 27% of variance), older age (9%), and baseline neuropathy (5%). The strongest predictors of hot/coldness in hands/feet were worse baseline neuropathy (11%) and fatigue/anxiety/depression (6%). Inflammation was a risk for CIPN, per more pro-inflammatory IFN-γ (12%) and IL-1β (6%) and less anti-inflammatory IL-10 (6%) predicting numbness/tingling and more IFN-γ (17%) and less IL-10 (9%) predicting hot/coldness in hands/feet. Conclusions. The strongest pre-chemotherapy predictors of CIPN included worse fatigue/anxiety/depression and baseline neuropathy. A pro-inflammatory state also predicted CIPN. Because this is an exploratory study, these results suggest specific outcomes (e.g., IL-1β) and effect size estimates for designing replication and extension studies. Trial Registration . NCT00924651

show abstract

Neuromodulation therapies and treatment-resistant depression

Cited by 12 publications

References 104 publications

Mood disorders and complementary and alternative medicine: a literature review

Mood disorders and complementary and alternative medicine: a literature review

Design and investigation of novel neural stimulation by magnetic resonance coupling

Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy

Contact Info

Product

Resources

About